Clinical trials: Rendu Osler Weber
Telangiectasia, Hereditary Hemorrhagic
Studies of Hereditary Hemorrhagic Telangiectasia
OBJECTIVES: I. Examine screening modalities for pulmonary vascular arteriovenous malformation (PAVM) in individuals with endoglin mutations. II.
- Trial name
- NCT00004648
- Volunteers
- 65 people
- Sponsor
- National Center for Research Resources (NCRR)
Hereditary Hemorrhagic Telangiectasia, HHT
Genotype-phenotype Association in Hereditary Hemorrhagic Telangiectasia
The present project aims to study the inflammatory and endothelial responses involved in the differences in clinical events related to both genotypes (ENG vs. ACVRL1) in HHT.
- Conditions
- Hereditary Hemorrhagic Telangiectasia, HHT, Rendu Osler Weber Disease
- Trial name
- Generate-HHT (NCT05550376)
- Testing
- Registry
- Where
- Spain
- Volunteers
- 85 people
- Sponsor
- Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
Hereditary Hemorrhagic Telangiectasia, Gastrointestinal Hemorrhage
Octreotide in Patients With GI Bleeding Due to Rendu-Osler-Weber
The purpose of this study is to determine whether long-acting octreotide is safe and effective in the treatment of patients with Rendu-Osler-Weber (e.g. HHT).
- Conditions
- Hereditary Hemorrhagic Telangiectasia, Gastrointestinal Hemorrhage, Anemia
- Trial name
- ROW (NCT02874326)
- Testing
- Octreotide LAR
- Where
- 2 sites in Netherlands
- Volunteers
- 15 people
- Sponsor
- Radboud University Medical Center
Hereditary Hemorrhagic Telangiectasia (HHT)
Pomalidomide for the Treatment of Bleeding in Hereditary Hemorrhagic Telangiectasia Longitudinal Assessment Study
This is a multicenter U.S. longitudinal study evaluating patients with hereditary hemorrhagic telangiectasia who participated in the PATH-HHT clinical trial of pomalidomide for the treatment of HHT.
- Trial name
- PATH-HHT ATLAS (NCT07018401)
- Testing
- Pomalidomide
- Where
- 11 sites in United States
- Volunteers
- 62 people
- Sponsor
- Massachusetts General Hospital
Osler-Rendu-Weber Disease, Osler-Rendu Disease
Screening Behavior in Adults With Hereditary Hemorrhagic Telangiectasia
This study will explore the factors that influence screening behaviors of adults diagnosed with hereditary hemorrhagic telangiectasia (HHT), an inherited condition in which blood vessel defects called arteriovenous malformations…
- Conditions
- Osler-Rendu-Weber Disease, Osler-Rendu Disease, Telangiectasia, Hereditary Hemorrhagic
- Trial name
- NCT00684879
- Where
- United States
- Volunteers
- 320 people
- Sponsor
- National Human Genome Research Institute (NHGRI)
Hereditary Hemorrhagic Telangiectasia, Epistaxis
Effects of Pazopanib on Hereditary Hemorrhagic Telangiectasia Related Epistaxis and Anemia (Paz)
During the Efficacy Study (Part B), the investigators will study whether Pazopanib, taken daily for 24 weeks, will reduce the severity of nose bleeds in patients with hereditary hemorrhagic telangiectasia (HHT).
- Conditions
- Hereditary Hemorrhagic Telangiectasia, Epistaxis, Anemia, Nosebleed
- Trial name
- Paz (NCT03850964)
- Testing
- Pazopanib
- Where
- 11 sites in United States
- Volunteers
- 70 people
- Sponsor
- Cure HHT
Hereditary Hemorrhagic Telangiectasia
A Study to Evaluate ALN-6400 in Healthy Volunteers and Patients With Hereditary Hemorrhagic Telangiectasia (HHT)
The purpose of this study is to: evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single ascending doses of ALN-6400 in healthy volunteers evaluate the efficacy, safety, tolerability and PD of…
- Trial name
- InsigHHT (NCT06659640)
- Testing
- ALN-6400
- Where
- 16 sites in United States, Australia and 4 more
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- Alnylam Pharmaceuticals
Vascular Liver Disease, Portal Vein Thrombosis
Vienna Vascular Liver Disease Study
The aim of this Register Trial is to systematically study the epidemiology, risk factors, liver function as well prognosis of patients with vascular liver diseases.
- Conditions
- Vascular Liver Disease, Portal Vein Thrombosis, Budd-Chiari Syndrome, Non-Cirrhotic Portal Hypertension
- Trial name
- VALID (NCT03541057)
- Where
- Austria
- Volunteers
- 200 people
- Sponsor
- Medical University of Vienna
Hereditary Hemorrhagic Telangiectasia (HHT), Epistaxis
Topical TOR-582 Treatment of Epistaxis in HHT
People with hereditary hemorrhagic telangiectasia (HHT) often experience frequent and severe nosebleeds that can disrupt daily life and lead to anemia, medical procedures, and reduced quality of life.
- Trial name
- NCT07667413
- Testing
- Topical sirolimus ointment
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Columbia University
Hereditary Hemorrhagic Telangiectasia, Osler Weber Rendu Disease
Propranolol for Epistaxis in Hereditary Hemorrhagic Telangiectasia Patients
Hereditary Hemorrhagic Telangiectasia (HHT) is a genetic disorder of angiogenesis associated with disabling epistaxis. Management of these nose bleedings requires more effective treatment.
- Trial name
- EPERO (NCT04113187)
- Testing
- Propranolol treatment
- Where
- France
- Volunteers
- 15 people
- Sponsor
- University Hospital, Bordeaux
Hereditary Hemorrhagic Telangiectasia (HHT)
A Trial of TER-1754 in Patients With Hereditary Hemorrhagic Telangiectasia
This is a Phase 1a/1b, multicenter study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of TER-1754 (a novel AKT1 inhibitor) in patients with HHT.
- Trial name
- NCT07255846
- Testing
- TER-1754
- Where
- United States
- Sponsor
- Terremoto Biosciences Inc.
Hereditary Hemorrhagic Telangiectasia (HHT), Osler Weber Rendu Disease
Harmony-HHT: ATV-1601 in Participants With Hereditary Hemorrhagic Telangiectasia (HHT)
This is a 2-part study evaluating ATV-1601 in participants with moderate to severe HHT. Part 1 is a randomized, double-blind, placebo-controlled study evaluating 3 dosing regimens of ATV-1601.
- Trial name
- NCT07601425
- Testing
- ATV-1601
- Where
- 7 sites in United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Atavistik Bio, Inc
Hereditary Hemorrhagic Telangiectasia (HHT)
Assess Safety and Efficacy of VAD044 in HHT Patients
Part I: The purpose of this Phase 1b proof of concept study, randomised, placebo controlled, double blind, multicentre study is to asssess safety and efficacy of 2 doses of VAD044 in adult HHT patients.
- Trial name
- NCT05406362
- Testing
- VAD044 Part I, VAD044 Part II
- Where
- 7 sites in United States, Belgium and 4 more
- Volunteers
- 75 people
- Sponsor
- Vaderis Therapeutics AG
Haemorrhagic Hereditary Telangiectasia
Institutional Registry of Haemorrhagic Hereditary Telangiectasia
The purpose of this study is to create an institutional and population-based registry of Haemorrhagic Hereditary Telangiectasia with a prospective survey based on epidemiological data, risk factors, diagnosis, prognosis…
- Trial name
- NCT01761981
- Where
- Argentina
- Volunteers
- 590 people
- Sponsor
- Hospital Italiano de Buenos Aires
Hereditary Hemorrhagic Telangiectasia
Tranexamic Acid and Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)
Hereditary hemorrhagic telangiectasia (HHT, Rendu-Osler-Weber Syndrome) is associated with frequent nosebleeds in the majority of cases.
- Trial name
- TAHHT (NCT01031992)
- Where
- Germany
- Volunteers
- 23 people
- Sponsor
- University Hospital, Saarland
HHT, Morbus Osler
Intranasal Submucosal Bevacizumab for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)
In a case series intranasal submucosal bevacizumab has been shown to reduce epistaxis in patients suffering from Hereditary Haemorrhagic Telangiectasia together with KTP Laser therapy.
- Conditions
- HHT, Morbus Osler, Epistaxis
- Trial name
- NCT01314274
- Testing
- Bevacizumab, NaCl
- Where
- Austria
- Volunteers
- 15 people
- Sponsor
- Medical University of Vienna
Hereditary Hemorrhagic Telangiectasia, Epistaxis
Pazopanib for the Treatment of Epistaxis in Hereditary Hemorrhagic Telangiectasia
Investigators will test the value of very low dose Pazopanib administered to patients with hereditary hemorrhagic telangiectasia for the reduction in the severity of nose bleeds in those with frequent and long duration bleeding…
- Trial name
- NCT03850730
- Testing
- Pazopanib
- Volunteers
- 30 people
- Sponsor
- Cure HHT